Loading…
Loading…
Carl Zeiss Meditec AG (CZMWY) Q3 2026 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management pointed to currency headwinds, soft equipment demand and pressure in China's intraocular lens business.
Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totaling 5,102 shares, a growth of 89.7% from the March 31st total of 2,690 shares. Based on an average daily volume of 8,140 shares, the short-interest
Carl Zeiss Meditec AG is rated a "Buy" despite recent operational weakness and geopolitical headwinds, especially in Asia-Pacific and North America. Sales declined 4.8% in Q1, with margin compression and a suspended 2025/2026 outlook due to weak demand across Asia-Pacific and North America. CZMWF now trades at a significant discount to peers, with a 2026 price target of $39.26, implying ~20% upside against a discounted multiple.
Shares of Carl Zeiss Meditec AG (OTCMKTS:CZMWY - Get Free Report) have been assigned a consensus rating of "Hold" from the six ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec is rated a 'Strong Buy' with higher share price target, reflecting significant undervaluation and robust fundamentals. The company achieved over €2.2B in revenue (+7.5% YoY), strong order backlog, and over 50% recurring revenue, enhancing earnings stability. Despite Chinese market headwinds and low yield (1.3%), the company's vertical integration, innovation, and market leadership support a premium valuation.
No recent filings indexed.